Rapport Therapeutics, Inc. (Ticker: RAPP US) is a clinical-stage biopharmaceutical company focused on discovering and developing transformational small molecule medicines for central nervous system (CNS) disorders. The company specializes in leveraging its RAP technology platform to develop CNS drugs targeting receptor variants and specific neuroanatomical regions associated with certain diseases. Rapport Therapeutics is expected to list on June 6, 2024, on NASDAQ. The firm is offering 8.0 million shares at a price range of $16.00 to $18.00. The expected market capitalization at offer is $601.4 million. The total offer size is $136.0 million. The offering is managed by Goldman Sachs, Jefferies, TD Cowen, and Stifel.